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The field of regenerative medicine is moving toward translation to clinical practice. However, there are still
knowledge gaps and safety concerns regarding stem cell-based therapies. Improving large animal models
and methods for transplantation, engraftment, and imaging should help address these issues, facilitating
eventual use of stem cells in the clinic.Introduction
In this Forum, we discuss the current
status, challenges, and major directions
for future development of animal models
to facilitate the use of stem cells in
regenerative medicine. The variety of
stem cell sources and a wide spectrum
of potential applications make the devel-
opment of universal recommendations
and guiding principles very challenging,
yet certain common themes and
possible solutions are emerging that
can increase the predictive validity of
animal models for regenerative medicine.
This report is based on discussions that
took place at a recent NIH workshop
on this topic (http://dpcpsi.nih.gov/orip/
documents/summary_of_the_improving_
animal_models.pdf).
Animal Models for Stem Cell-Based
Regenerative Medicine: Mice
versus Large Animal Models
The discovery of mouse embryonic stem
cells (ESCs) in 1981 revolutionized the
study of developmental biology, and
mice are now used extensively to study
stem cell biology. However, there are limi-
tations to their application as models for
regenerative medicine. Mouse models
do not reproduce in full certain human
disease conditions. For example, labora-
tory mice are insulin resistant and proneto cancer and renal failure. They are
relatively obese and hypertensive due to
the constant access to food. In compar-
ison to humans, mice have small body
size, short lifespan, and substantially
different physiology. Significant progress
has been made in the creation and use
of humanized mice. There are, how-
ever, disadvantages to using the current
strains, including complications in repro-
ducing standard chimeras, limitations
in choices of human cell types that can
be used for xenotransplantation, residual
host immunoreactivity, and problems
with translating conditioning regiments
between species. The evolutionary dis-
tance between donor and recipient
animals will also affect the survival of
transplanted stem cells due to species
differences in trophic properties of
tissues.
Larger animal species, which were crit-
ical for developing hematopoietic stem
cell therapies, often have an enhanced
ability to predict clinical efficacy relative
to mice. The utilization of large animal
models is expected to increase and,
therefore, further development of large
animal stem cell technologies will also
be required. It will be critical to select
the large animal that is most appropriate
for each potential therapy in humans.
The pig has emerged as one of the bestCell Stem Cellexamples of a large animal model
currently being used to study human
genetic diseases (review in Kuzmuk and
Schook, 2011). Even without genetic
modification, minipigs and full-size
breeds have been widely used for
studying infectious diseases, cardiovas-
cular disease and atherosclerosis, wound
healing, digestive processes, diabetes,
ophthalmology, and some cancers, as
well as providing organs for xenotrans-
plantation. The value of pigs as biomed-
ical models has been enhanced over the
last decade by targeting specific genomic
sites for modification. Swine disease
models created by targeted genetic engi-
neering include those for cystic fibrosis,
Alzheimer’s and Huntington’s disease,
retinitis pigmentosa, hyperlipoproteine-
mia, and muscular dystrophy. Recently,
creation of humanized pigs has been re-
ported (Suzuki et al., 2012), as well as
improved preclinical disease models suit-
able for testing stem cell therapies in pigs
(Giraud et al., 2011; McCall et al., 2012).
Most of this work has been enhanced
through access to the swine genome
sequence and the use of inbred
minipigs (http://www.nsrrc.missouri.edu/
strainavail.asp). Work in swine will
complement nonhuman primate research
for neurological treatments when ana-
lyzing recovery of fine motor skills or12, March 7, 2013 ª2013 Elsevier Inc. 271
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would be facilitated by equivalent
advances in primate transgenesis, like
the recent monkey models of Hunting-
ton’s disease.
Major challenges remain, however, for
using large animals in stem cell research.
For example, there is limited availability
of species-specific reagents, such as
antibodies and growth factors, and
fully annotated expression microarrays.
Authenticated ESCs have been difficult
to generate from large domestic species,
such as dog, swine, cattle, sheep, and
goats. This has been obviated in part by
creation of induced pluripotent stem cells
(iPSCs) from these species by standard
reprogramming technologies. There is
a lack of centralized resources where
cells can be characterized and stored,
reagents made available, and databases
maintained for the wider biomedical
community. If these barriers can be over-
come, well-characterized large animal
stem cells can provide an appropriate
choice of animal models for particular
human disease conditions and medical
applications. These studies will comple-
ment the use of mice, leading to more
comprehensive studies that can then be
applied to humans.
Animal Induced Pluripotent Stem
Cells as Emerging Models for
Human Therapeutic Applications
The field of stem cell research experi-
enced a dramatic new direction with the
isolation of iPSCs from humans and
mice. Several studies on various animal
systems suggest that the basic pluripo-
tency network appears to be conserved
among different species, allowing deriva-
tion of iPSCs from a variety of large animal
species, including pigs, monkeys, dogs,
and several others (Plews et al., 2012).
As for the human, iPSCs from ungulates
and monkeys are of epiblast type, and
fibroblast growth factor 2 and activin-
nodal signaling systems are critical for
their growth in culture and for mainte-
nance of pluripotency. Animal iPSCs
should be of value as a renewable source
of cells for testing safety after progenitor
cells are introduced as a tissue graft and
for testing surgical and related technolo-
gies required before human trials can
proceed. Many of the challenges that
face human iPSC research apply to
animal iPSCs as well, including issues272 Cell Stem Cell 12, March 7, 2013 ª2013related to safety, efficiency, and differen-
tiation potential.
Several problems remain before the
potential of nonrodent animal iPSCs can
be realized. Cell lines must be character-
ized in more detail, chimerism tested,
and reprogramming increased in effi-
ciency and speed in order to enhance
genome integrity. Cell surface markers
can be inconsistent among various lines
and cell populations may be heteroge-
neous, probably reflecting different
stages of reprogramming. Efficient deri-
vation of animal iPSC lines requires
further development of technologies for
generating the cells, preferentially avoid-
ing gene integration and potential risks
of tumorigenesis.
An important aspect of animal studies is
the ability to test immune responses to
iPSCs and their derivatives. A number of
animal studies have reported that iPSCs
can form teratomas and other types of
tumors in immunodeficient, allogeneic,
syngeneic, and xenogeneic recipients
due to the inability of the host to re-
ject teratoma-inducing cells. The innate
immune system appears capable of
dealing with small numbers of undifferen-
tiated iPSCs that might be present in
grafts, despite efforts to eliminate them.
The ability of adaptive and innate immune
reactions to weaken engraftment of syn-
geneic stem cell transplants is another
important aspect of the host reaction
that can affect the efficiency of cell
transplantation. There is an urgent need
to test immune reactions against thera-
peutic iPSC derivatives and a small
number of potentially tumorigenic cells.
Larger animal species have important
advantages as model systems in this
regard since their immunophysiology is
closer to humans than to rodents. Like
humans, larger animal models have
developed as outbred populations over
time, thus shaping genomic adaptations.
Rodent models will remain important
tools for immunological discovery and
proof of concept, whereas larger animal
models will be critical for successful
translation for clinical applications of
iPSCs.
iPSCs from patients have the potential
to help identify the molecular and cellular
basis of human disease by ‘‘disease-in-
a-dish’’ modeling. Though this field is still
in its infancy, reports thus far indicate the
general ability of iPSCs to recapitulateElsevier Inc.certain cellular abnormalities of the corre-
sponding cells from patients with various
Mendelian disorders. The ability to model
low-penetrance phenotypes, late-onset
disorders, and genetically complex disor-
ders, however, remains to be proved.
Animal model systems may help solve
some of these problems because trans-
plantation experiments can be performed
using the animal as a host. The use of
allogeneic iPSCs in animal model systems
or xenotransplantation of human stem
cells in immunocompromised or human-
ized animals should facilitate analysis of
disease phenotypes that require cellular
interactions in the tissues. Animal iPSCs
can have certain advantages for testing
hypotheses regarding the influence of
environmental or epigenetic components
of disease first identified in cell culture.
The effects of exposures and genomic
modifications can be tested at the level
of the tissue, organ, and the whole animal,
preserving interactions among distinct
cell types in vivo. Use of animal systems
also facilitates experimental design by
providing controls with matching genetic
background, age, gender, and exposure
history.
Improving Stem Cell
Transplantation: Engraftment and
Imaging
Two different approaches can be taken
for stem cell-based therapies. The first is
transplantation, in which stem cells, or
derived progenitor or differentiated cells,
are delivered directly to the body. The
second approach relies on activation of
endogenous stem and progenitor cells
or somatic cells reprogrammed in situ.
Studies in animal model systems and in
humans indicate significant cell death
after transplantation and limited engraft-
ment and differentiation of transplanted
stem cells. Retention and survival of
transplanted cells must be improved.
One of the likely reasons for low levels
of cell survival and engraftment is the
absence of the proper cellular environ-
ment and substrate for engraftment.
Attempts have been made to provide
the transplanted cells with biomaterial
carriers and signaling molecules, which
will prevent cell death and will help to re-
establish proper cell interactions. Among
techniques that are currently under devel-
opment to address these problems in
animal models are genetic modification
Cell Stem Cell
Forumof the cells and the use of tissue-
engineering techniques involving three-
dimensional biodegradable scaffolds,
additional types of support cells, and
other bioactive molecules. Various nano-
materials have been explored to control
stem cell behavior such as adhesion
and differentiation by modulating biomi-
metic characteristics and mechanical
properties.
An important goal of stem cell-based
therapies for treatment of damaged or
diseased tissues is to establish proper
connections between cells or with extra-
cellular signaling molecules. This has
been challenging for cardiovascular repair
and even more complicated for stem cell-
mediated transplantation in the retina
or brain, where appropriate synaptic
connections must be created within
the three-dimensional tissue structure.
Knowledge of the homing and niche
signals that mediate the activation, migra-
tion, and integration of stem cells to
damaged tissues is limited. Cytokines,
growth factors, adhesion molecules,
cell-cell contacts, and small metabolic
products are active players in these
processes. These mechanisms may vary
among different animal species and
should be investigated and evaluated in
a search for the most appropriate model
for a particular application. Progress has
been made, for example, in the use of
synthetic and natural guide materials,
nerve guide coatings, topographical
cues, special scaffolds, and support cells
to guide nerve cell engraftment (Bell
and Haycock, 2012). Pharmacologically
active microcarriers, such as biodegrad-
able and noncytotoxic poly lactic-co-
glycolic acid microspheres covered with
extracellular matrix molecules, have
been successfully tested in animal
models of Parkinson’s disease and
infarcted myocardium in rats and mini-
pigs, respectively.
Cellular imaging is a high priority for
basic research and clinical translation in
regenerative medicine. Imaging is impor-
tant for several applications, including
guiding and verifying the accuracy of
cell injection, tracking cell migration, sur-
vival, and behavior, evaluating off-target
effects, and monitoring long-term cell
engraftment. Reagents should be opti-
mized that exhibit quantitative biosensing
properties and functional readouts that
can report changes in cell conditions,such as activation, differentiation, or
injury. These parameters in most cases
cannot be obtained from patients via
direct sample extraction, in distinction
to animal studies. The development
of noninvasive imaging approaches to
monitor transplanted stem cell behavior
is critical for future translation to clinics.
Significant advances have been
achieved in the use of imaging modalities
such as single-photon emission com-
puted tomography (SPECT), positron
emission tomography (PET), and MRI to
monitor noninvasively transplanted cells
in myocardium, skin hair follicles, the
CNS, bone marrow, mammary glands,
and retina, as well as other organs in
rodents. The development of imaging
techniques in large animals is becoming
increasing important, due to the applica-
tion of protocols and equipment more
relevant to the clinical setting. Among
complications are the need for equip-
ment accommodating larger species,
limited tissue penetration, and the
outbred nature of large animals, which
may require more animals and longer
analysis time. Large animals will also
demand additional knowledge of their
biology and careful monitoring of physio-
logical parameters during imaging pro-
cedures. MRI has been used to detect
nanoparticle-labeled cells in large animals
in several studies, but the approach was
limited by label leakage and uptake
by macrophages. Cells have also been
labeled with a variety of radionuclides.
Limitations of several isotopes were rela-
tively short half-life and effects on cell
viability. Good results were obtained by
using a PET-herpes simplex virus thy-
midine kinase-reporter system. Stable
expression for an extended period of
time was reported recently with PET or
SPECT after administration of radiotracer
in combination with expression of a trans-
genic sodium iodide symporter (NIS) in
a pig model of myocardial infarction
(Templin et al., 2012). Another successful
study has been reported in pigs using
iPSC-derived endothelial cells labeled
with [18F]- fluorodeoxyglucose for PET
imaging and iron particles for colocaliza-
tion with MRI (Gu et al., 2012). New,
more sophisticated PET/SPECT reporter
genes will require addressing potential
oncogenicity and immunogenicity of
transplanted cells. No single imaging
technique provides all of the desired infor-Cell Stem Cellmation, permitting single-cell detection
in an animal model. However, current
techniques should allow optimization of
procedures and on future improvement
should satisfy most needs, thus facili-
tating cell tracking in humans.
How Animal Models Can Address
the Potential Challenges of Stem
Cell Therapy
The challenges associated with unique
properties of stem cells that must be
understood before moving to clinical
applications have been identified and
continue to grow. Among these are
genetic instability, high mutation rate
and tumorigenic potential, epigenetic
memory of differentiated iPSCs, and the
immune response after stem cell trans-
plantation. Some of these concerns
became evident during experiments
when animal stem cells were tested and
should be examined rigorously for human
stem cells. Importantly, animal models
will be critical to evaluate new potential
hazards and to address these problems
(Frey-Vasconcells et al., 2012). The stan-
dard use of preclinical animal models for
studies that include adsorption, distribu-
tion, metabolism, excretion, and toxi-
cology is mandated by the US Food and
Drug Administration. The validated pro-
cesses and regulatory requirements are
well established for these studies. How-
ever, even in these investigations, there
are issues as to whether the standard
models are appropriate for cell-based
therapy. For example, biodistribution
with pathology analysis using sequential
sections of the entire body may not be
an appropriate model for a localized cell
transplant that is not expected to survive
in an allogeneic setting. A number of
special considerations should be taken
into account when designing tumorige-
nicity studies, such as the animal species
for testing, the type and condition of ther-
apeutic stem cells or their byproducts,
in vivo survival time, and potential distri-
bution and migration of the transplanted
cells. Several concerns were reported
based on mouse studies that employed
a variety of cell types, including mesen-
chymal stem cells (MSCs). Extensive
preclinical data using MSCs from larger
animal species (pigs, dogs, and sheep)
for transplantation as well as clinical
studies have not detected a major risk
for tumor growth. The following reasons12, March 7, 2013 ª2013 Elsevier Inc. 273
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between preclinical and clinical studies
at least in regard toMSCs and their poten-
tial applications for treatment of heart
disease: substantial differences in mouse
and larger animals and human cell
behavior in culture, differentiation capac-
ities of particular cell preparations, sensi-
tivity to triggers of transformation, and
properties of the immune surveillance
systems (Hatzistergos et al., 2011). Very
limited information is available regarding
other types of transplanted cells and
animal model species to make a valid
selection of the most predictable model.
Rigorous studies should be conducted
for each application to evaluate the onco-
genic risk of the use of stem cell products
in the most appropriate model system,
especially large animals.
Conclusions
Insufficient knowledge of human stem
cell biology and the absence of animal
models that precisely recapitulate partic-
ular human disease phenotypes, with
comparable organ size and physiology,
are currently significant limitations for the
progress of regenerative medicine. Im-
provement of existing rodent models, as
well as development and characterization
of stable stem cell lines and disease274 Cell Stem Cell 12, March 7, 2013 ª2013models from larger animal species, will
take place in concert with other innovative
approaches, such as microsystem tissue
engineering and in vitro modeling of
human disease pathways by using iPSCs
from affected individuals. These various
approaches are complementary and are
highly relevant to the future of stem cell-
based regenerative medicine. However, it
is also clear that extant models need to
be modified, new models developed, and
rigorous standards of preclinical evalua-
tion followed to maximize their research
value. There is no single, perfect animal
model that can completely predict the
outcome of clinical trials. The challenge is
to collect relevant and sufficient informa-
tion from as many models as are required
to make an informed decision regarding
the potential benefits and risks to patients.
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